HCA Healthcare, Inc. $HCA Shares Sold by New York State Common Retirement Fund

New York State Common Retirement Fund trimmed its holdings in shares of HCA Healthcare, Inc. (NYSE:HCA) by 5.5% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 316,402 shares of the company’s stock after selling 18,346 shares during the period. New York State Common Retirement Fund owned about 0.14% of HCA Healthcare worth $121,214,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Park Place Capital Corp raised its stake in HCA Healthcare by 2,336.0% during the second quarter. Park Place Capital Corp now owns 1,218 shares of the company’s stock worth $474,000 after purchasing an additional 1,168 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of HCA Healthcare by 11.9% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 25,454 shares of the company’s stock worth $8,796,000 after buying an additional 2,698 shares during the period. Swiss National Bank grew its position in HCA Healthcare by 4.3% during the second quarter. Swiss National Bank now owns 558,900 shares of the company’s stock valued at $214,115,000 after acquiring an additional 23,100 shares during the period. Cherokee Insurance Co acquired a new position in shares of HCA Healthcare in the 2nd quarter valued at about $3,869,000. Finally, Harrell Investment Partners LLC increased its position in HCA Healthcare by 176.3% during the 2nd quarter. Harrell Investment Partners LLC now owns 1,815 shares of the company’s stock worth $695,000 after purchasing an additional 1,158 shares in the last quarter. Hedge funds and other institutional investors own 62.73% of the company’s stock.

Analyst Ratings Changes

HCA has been the subject of several research reports. Robert W. Baird boosted their price objective on shares of HCA Healthcare from $380.00 to $423.00 and gave the stock a “neutral” rating in a research note on Thursday, August 14th. Oppenheimer raised their price objective on HCA Healthcare from $400.00 to $500.00 and gave the company an “outperform” rating in a research report on Monday, October 27th. TD Cowen upped their target price on HCA Healthcare from $380.00 to $490.00 and gave the stock a “buy” rating in a research report on Monday, October 27th. Sanford C. Bernstein reissued a “market perform” rating and set a $417.00 price target on shares of HCA Healthcare in a research report on Monday, October 27th. Finally, KeyCorp lifted their price objective on shares of HCA Healthcare from $465.00 to $475.00 and gave the company an “overweight” rating in a research note on Monday, October 27th. Fourteen equities research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $474.53.

Insider Buying and Selling

In other news, EVP Michael S. Cuffe sold 3,836 shares of the firm’s stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $418.84, for a total value of $1,606,670.24. Following the transaction, the executive vice president directly owned 31,503 shares in the company, valued at approximately $13,194,716.52. This trade represents a 10.85% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Michael R. Mcalevey sold 3,892 shares of the business’s stock in a transaction dated Wednesday, November 5th. The shares were sold at an average price of $473.79, for a total transaction of $1,843,990.68. Following the sale, the executive vice president directly owned 3,487 shares of the company’s stock, valued at approximately $1,652,105.73. This represents a 52.74% decrease in their position. The SEC filing for this sale provides additional information. 1.30% of the stock is currently owned by insiders.

HCA Healthcare Trading Down 0.4%

HCA Healthcare stock opened at $512.94 on Friday. The stock has a 50 day moving average of $452.07 and a 200-day moving average of $406.38. The stock has a market cap of $117.05 billion, a P/E ratio of 19.83, a price-to-earnings-growth ratio of 1.38 and a beta of 1.41. HCA Healthcare, Inc. has a 52 week low of $289.98 and a 52 week high of $520.00.

HCA Healthcare (NYSE:HCA) last posted its quarterly earnings data on Friday, October 24th. The company reported $6.96 EPS for the quarter, beating analysts’ consensus estimates of $5.64 by $1.32. The firm had revenue of $19.16 billion for the quarter, compared to the consensus estimate of $18.55 billion. HCA Healthcare had a net margin of 8.53% and a negative return on equity of 792.25%. The firm’s revenue was up 9.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $4.90 EPS. HCA Healthcare has set its FY 2025 guidance at 27.000-28.000 EPS. As a group, equities analysts predict that HCA Healthcare, Inc. will post 24.98 earnings per share for the current fiscal year.

HCA Healthcare Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, December 29th. Shareholders of record on Monday, December 15th will be issued a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend is Monday, December 15th. HCA Healthcare’s dividend payout ratio (DPR) is currently 11.13%.

HCA Healthcare Profile

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.